source
- Valneva's Shigella vaccine cuts infection rates in phase 2 trialValneva reported that its Shigella vaccine reduced the number of intestinal infections in a phase 2 controlled human infection model study conducted in the United States. The trial enrolled 120 he…
- ARPA-H teams meet FDA within two months of launching autonomous clinical AI programMultiple teams in ARPA-H's Advocate program, which focuses on autonomous clinical AI tools, have already held an initial informational meeting with the FDA. The meeting took place less than two mo…